ATE473758T1 - Her-2/neu multipeptidimpfstoff - Google Patents

Her-2/neu multipeptidimpfstoff

Info

Publication number
ATE473758T1
ATE473758T1 AT06007834T AT06007834T ATE473758T1 AT E473758 T1 ATE473758 T1 AT E473758T1 AT 06007834 T AT06007834 T AT 06007834T AT 06007834 T AT06007834 T AT 06007834T AT E473758 T1 ATE473758 T1 AT E473758T1
Authority
AT
Austria
Prior art keywords
new
vaccine
multipeptide vaccine
multipeptide
neu
Prior art date
Application number
AT06007834T
Other languages
English (en)
Inventor
Christoph Zielinski
Otto Schreiner
Hubert Pehamberger
Heimo Breiteneder
Ursula Wiedermann
Original Assignee
Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh filed Critical Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh
Application granted granted Critical
Publication of ATE473758T1 publication Critical patent/ATE473758T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06007834T 2006-04-13 2006-04-13 Her-2/neu multipeptidimpfstoff ATE473758T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007834A EP1844788B1 (de) 2006-04-13 2006-04-13 HER-2/neu Multipeptidimpfstoff

Publications (1)

Publication Number Publication Date
ATE473758T1 true ATE473758T1 (de) 2010-07-15

Family

ID=37110206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06007834T ATE473758T1 (de) 2006-04-13 2006-04-13 Her-2/neu multipeptidimpfstoff

Country Status (9)

Country Link
US (1) US20090269364A1 (de)
EP (2) EP1844788B1 (de)
AT (1) ATE473758T1 (de)
AU (1) AU2007237491B2 (de)
CA (1) CA2649013C (de)
DE (1) DE602006015421D1 (de)
ES (1) ES2348312T3 (de)
IL (1) IL194162A (de)
WO (1) WO2007118660A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
EP2376089B1 (de) * 2008-11-17 2018-03-14 The Regents of the University of Michigan Krebsvakzine-zusammensetzungen und anwendungsverfahren dafür
CA2768346A1 (en) * 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
EP2292258A1 (de) * 2009-08-18 2011-03-09 Pevion Biotech Ltd. Multiepitop-Impfstoff für Her2/neu-assoziierten Krebs
BR112014012460B1 (pt) * 2011-11-23 2021-01-12 Bioven 3 Limited proteínas recombinantes
US20150071987A1 (en) * 2012-02-03 2015-03-12 Emory University Immunostimulatory compositions, particles, and uses related thereto
RU2726411C2 (ru) 2015-04-17 2020-07-14 Биолайф Сайенс Клд Лимитед Вакцинная композиция и ее применения
WO2016184862A1 (en) * 2015-05-18 2016-11-24 Oncoqr Ml Gmbh Her2/neu immunogenic composition
EP3576764A4 (de) 2017-02-03 2020-12-16 The Medical College of Wisconsin, Inc. Kras-peptid-impfstoffzusammensetzungen und verfahren zur verwendung
WO2019116089A2 (en) 2017-12-11 2019-06-20 Medizinische Universitaet Wien A method of producing a vaccine composition and uses thereof
CA3145363A1 (en) * 2019-07-02 2021-01-07 Virago Vax Inc. Mammary tumor virus vaccine
US12029783B2 (en) 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117165A (ja) * 1991-10-24 1993-05-14 Masakazu Ueda 抗癌剤
JP4658423B2 (ja) * 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
ES2394293T3 (es) * 2001-02-28 2013-01-30 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna contra cánceres que están asociados con el oncogén HER-2/neu
JP4369662B2 (ja) * 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー

Also Published As

Publication number Publication date
DE602006015421D1 (de) 2010-08-26
WO2007118660A2 (en) 2007-10-25
EP1844788B1 (de) 2010-07-14
CA2649013C (en) 2017-05-02
EP1844788A1 (de) 2007-10-17
ES2348312T3 (es) 2010-12-02
AU2007237491A1 (en) 2007-10-25
CA2649013A1 (en) 2007-10-25
IL194162A (en) 2014-04-30
WO2007118660A3 (en) 2007-12-13
IL194162A0 (en) 2011-08-01
AU2007237491B2 (en) 2012-11-01
EP2004218A2 (de) 2008-12-24
US20090269364A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
IL194162A0 (en) Her-2/neu multi-peptide vaccine
PH12014501083A1 (en) Anticancer fusion protein
PH12013500714A1 (en) Anticancer fusion protein
CL2009001258A1 (es) Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
WO2008046911A3 (en) Novel human micrornas associated with cancer
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
NZ611108A (en) Methods of treating fgf21-associated disorders
BRPI0807896A2 (pt) Fórceps bipolares não-aderentes.
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
PT1764127E (pt) Grampo de protecção de agulha com porção de salto
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
BR112014019901A2 (pt) proteínas de fator viii recombinante
EA201000865A1 (ru) Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
WO2008136869A3 (en) Methods and compositions related to targeting wounds, regenerating tissue, and tumors
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
WO2008153933A3 (en) Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
MX2010001856A (es) Proteina.
AR076892A1 (es) Conjugados de albumina-peptido amiloide y usos de los mismos
ATE538660T1 (de) Verfahren zur herstellung eines weizenproteinhydrolysats
PL394618A1 (pl) Przeciwnowotworowe bialko fuzyjne
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
WO2010052243A3 (en) Neurotensin-derived branched peptides and uses thereof
MX2010010177A (es) Fragmentos de beta timosina mejorada.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1844788

Country of ref document: EP